PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
17.97%
EBIT growth of 17.97% while Biotechnology median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
17.97%
Operating income growth of 17.97% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand.
18.43%
Net income growth of 18.43% while Biotechnology median is zero. Walter Schloss might see potential if moderate gains can keep rising.
58.16%
EPS growth of 58.16% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
58.16%
Diluted EPS growth of 58.16% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
96.23%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
96.23%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
22.94%
OCF growth of 22.94% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
22.94%
FCF growth of 22.94% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-567.72%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
90.81%
OCF/share CAGR of 90.81% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
89.23%
3Y OCF/share growth of 89.23% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-636.46%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
93.35%
Net income/share CAGR of 93.35% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
88.82%
3Y net income/share CAGR of 88.82% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
2271.09%
Equity/share CAGR of 2271.09% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-76.58%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-2.44%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
569.03%
Asset growth of 569.03% while Biotechnology median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
756.79%
BV/share growth of 756.79% while Biotechnology is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-16.19%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
-15.49%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-24.67%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.